Edgar Staren, MD, Ph.D., MBA Presents at American Society of Breast Surgeons 15th Annual Meeting - WMBB News 13 - The Panhandle's News Leader

Edgar Staren, MD, Ph.D., MBA Presents at American Society of Breast Surgeons 15th Annual Meeting

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Cancer Treatment Centers of America

 

SCHAUMBURG, Ill., May 5, 2014 /PRNewswire-USNewswire/ -- Edgar Staren, MD, Ph.D., MBA, President and CEO of Cancer Treatment Centers of America® (CTCA) Medicine and Science has been selected to present new research on approaches to the treatment of primary and recurrent breast cancer at the American Society of Breast Surgeons 15th Annual Meeting in Las Vegas, NV on Friday, May, 2, 2014.  Dr. Staren presented his abstract titled "Initial Experience with Genomic Profiling of Breast Cancers." 

Cancer Treatment Centers Of America logo

Dr. Staren, along with Donald Braun, Ph.D., MS, Chief Science Officer and Vice President of Translational Research; Maurie Markman, MD, Senior Vice President of Clinical Affairs & National Director of Medical Oncology; Bradford Tan, MD, Lead Chief of Staff and National Director Pathology and Laboratory Medicine; Kim Kramer and Roxanna Geana examined the rapidly evolving advances of theorized unique "driver mutations" within individual patient's cancers, as well as the dramatic reduction in cost associated with obtaining genomic profiles for the role of testing in routine clinical practice. 

The research found that almost all advanced breast cancers possess at least one well-characterized genomic alteration.   Further, in the majority of cases there is a plausible argument that can be advanced for potential biological and clinical relevance of an FDA-approved anti-neoplastic agent not currently indicated in the treatment of breast cancer.  The research also identified that next steps will include further defining the actual clinical relevance of genetic alterations in the evaluation process. 

"This research helps us understand the potential power of genomic testing," said Dr. Staren. "Our goal is to better target and better attack an individual's unique cancer.  With this study, we have been able to take a number of patients and provide them a novel treatment plan based off the genomic profiling.  I am honored to address and collaborate with the esteemed group of breast cancer experts participating in this annual meeting, and hope they find the prospect of genomic testing as exciting as we do."

About Cancer Treatment Centers of America®

Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer.  CTCA offers a comprehensive, fully integrative approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa.  Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.

Logo - http://photos.prnewswire.com/prnh/20090612/CTCALOGO

©2012 PR Newswire. All Rights Reserved.